Sales Help Allergan Revenue Exceed Forecast

Allergan Inc.’s second-quarter revenue was stronger than expected, primarily because of continued growth in sales of its Alphagan and Botox drugs as well as strong sales of other pharmaceutical products to U.S. wholesalers, the Irvine company said Tuesday. Revenue totaled $284.5 million in the second quarter last year.

Allergan also said it signed agreements granting Japan’s Santen Pharmaceutical Co. exclusive distribution rights for Alphagan in that country. Under the agreements, Santen will assume responsibility for future product development of Alphagan, which lowers pressure in the eye. Santen also is responsible for obtaining Japanese government approval for the product.

Botox, which contains the toxin botulinum, is used to treat muscle spasms in eyelids and to remove wrinkles.